CARM
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Oct 17 closing price
Capitalization
6.43M
IONS
Price
$73.09
Change
+$0.02 (+0.03%)
Updated
Oct 17 closing price
Capitalization
11.65B
11 days until earnings call
Interact to see
Advertisement

CARM vs IONS

Header iconCARM vs IONS Comparison
Open Charts CARM vs IONSBanner chart's image
Carisma Therapeutics
Price$0.04
Change-$0.00 (-0.00%)
Volume$573.15K
Capitalization6.43M
Ionis Pharmaceuticals
Price$73.09
Change+$0.02 (+0.03%)
Volume$1.31M
Capitalization11.65B
CARM vs IONS Comparison Chart in %
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. IONS commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (CARM: $0.04 vs. IONS: $73.09)
Brand notoriety: CARM and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 5% vs. IONS: 50%
Market capitalization -- CARM: $6.43M vs. IONS: $11.65B
CARM [@Biotechnology] is valued at $6.43M. IONS’s [@Biotechnology] market capitalization is $11.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 3 bullish TA indicator(s).

  • CARM’s TA Score: 4 bullish, 6 bearish.
  • IONS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both CARM and IONS are a bad buy in the short-term.

Price Growth

CARM (@Biotechnology) experienced а -76.22% price change this week, while IONS (@Biotechnology) price change was +4.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

IONS is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($11.6B) has a higher market cap than CARM($6.43M). IONS YTD gains are higher at: 109.067 vs. CARM (-91.261). CARM has higher annual earnings (EBITDA): -44.04M vs. IONS (-170.69M). IONS has more cash in the bank: 2.29B vs. CARM (2M). CARM has less debt than IONS: CARM (1.7M) vs IONS (1.42B). IONS has higher revenues than CARM: IONS (944M) vs CARM (10.8M).
CARMIONSCARM / IONS
Capitalization6.43M11.6B0%
EBITDA-44.04M-170.69M26%
Gain YTD-91.261109.067-84%
P/E RatioN/AN/A-
Revenue10.8M944M1%
Total Cash2M2.29B0%
Total Debt1.7M1.42B0%
FUNDAMENTALS RATINGS
CARM vs IONS: Fundamental Ratings
CARM
IONS
OUTLOOK RATING
1..100
224
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9936
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CARM's Valuation (89) in the null industry is in the same range as IONS (100) in the Biotechnology industry. This means that CARM’s stock grew similarly to IONS’s over the last 12 months.

IONS's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for CARM (100) in the null industry. This means that IONS’s stock grew somewhat faster than CARM’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that IONS’s stock grew similarly to CARM’s over the last 12 months.

IONS's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for CARM (99) in the null industry. This means that IONS’s stock grew somewhat faster than CARM’s over the last 12 months.

IONS's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for CARM (100) in the null industry. This means that IONS’s stock grew somewhat faster than CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMIONS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 2 days ago
65%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 12 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DECZ40.710.17
+0.42%
TrueShares Structured Outcome Dec ETF
STXM28.140.02
+0.06%
Strive Mid-Cap ETF
BHYB54.49N/A
N/A
Xtrackers USD High Yld BB-B ex Fin ETF
GBXC26.52N/A
N/A
Goldman Sachs U.S. Lg Cp Buffr 3 ETF
NUW14.17-0.04
-0.28%
Nuveen AMT-Free Municipal Value Fund

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with EVGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then EVGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-13.93%
EVGN - CARM
57%
Loosely correlated
-2.34%
INSM - CARM
45%
Loosely correlated
+1.57%
IONS - CARM
33%
Poorly correlated
+0.03%
CYTK - CARM
32%
Poorly correlated
-0.88%
VCYT - CARM
31%
Poorly correlated
+0.06%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with CYTK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+0.03%
CYTK - IONS
64%
Loosely correlated
-0.88%
MLYS - IONS
51%
Loosely correlated
+1.37%
ARWR - IONS
51%
Loosely correlated
-5.54%
MNKD - IONS
48%
Loosely correlated
+2.24%
RARE - IONS
48%
Loosely correlated
-3.93%
More